DARATUMUMAB AND HYALURONIDASE-FIHJ (HUMAN RECOMBINANT)

0 reported adverse events

Drug classes: CD38-directed Cytolytic Antibody [EPC] Endoglycosidase [EPC]

These side effects are most commonly reported by patients taking DARATUMUMAB AND HYALURONIDASE-FIHJ (HUMAN RECOMBINANT):

# Side effect Count
See all common reactions for DARATUMUMAB AND HYALURONIDASE-FIHJ (HUMAN RECOMBINANT)

DARATUMUMAB AND HYALURONIDASE-FIHJ (HUMAN RECOMBINANT) is most commonly taken among patients reporting these side effects:

# Side effect Count Frequency
See all enriched reactions for DARATUMUMAB AND HYALURONIDASE-FIHJ (HUMAN RECOMBINANT)